Last updated: September 8, 2026
Cutaquig is Octapharma’s 16.5% subcutaneous immunoglobulin, or SCIG, marketed for primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy, or CIDP. Its commercial outlook is supported by the shift from hospital-administered IVIG to home-based immunoglobulin therapy, expansion into CIDP, and continued demand for plasma-derived products. Octapharma does not disclose Cutaquig-specific sales, so its financial trajectory must be assessed through company-level immunoglobulin revenue, regulatory expansion, market access, and competitive positioning.
What is Cutaquig and which patients does it treat?
Cutaquig is a human normal immunoglobulin solution containing 16.5% immunoglobulin G for subcutaneous administration. Octapharma manufactures and commercializes the product in the United States and international markets.
The U.S. Food and Drug Administration approved Cutaquig in December 2018 for adults and pediatric patients aged 2 years and older with primary humoral immunodeficiency diseases. FDA later approved Cutaquig for maintenance therapy in adults with CIDP. The CIDP indication broadened the addressable market beyond patients with antibody deficiency and placed Cutaquig in competition with established SCIG and IVIG products used in neurology.[1]
FDA regulatory status
| Item |
Status |
| Active ingredient |
Human normal immunoglobulin |
| Concentration |
16.5% |
| U.S. dosage form |
Subcutaneous injection |
| Initial U.S. approval |
December 2018 |
| Primary U.S. indication |
Primary humoral immunodeficiency diseases |
| Additional U.S. indication |
Maintenance therapy for adult CIDP |
| Administration setting |
Home or outpatient subcutaneous infusion |
| Regulatory pathway |
Biologics license application |
| Product category |
Plasma-derived biologic |
Cutaquig is administered through a pump using one or more subcutaneous infusion sites. The higher concentration allows delivery of the required immunoglobulin dose in lower volume than some 10% SCIG products, although the practical benefit depends on patient dose, infusion equipment, site tolerance, and nursing support.
How large is the Cutaquig market?
The relevant market is the broader immunoglobulin market, divided between IVIG and SCIG. Immunoglobulin demand is structurally supported by chronic replacement therapy, neurological indications, hematology use, and continued diagnosis of immunodeficiency disorders.
SCIG has gained share because it can reduce infusion-center visits, support home administration, and provide more stable immunoglobulin exposure than intermittent IVIG. The transition is strongest in primary immunodeficiency, where patients often require lifelong therapy. In CIDP, the commercial opportunity is meaningful but more competitive because IVIG remains widely used and treatment decisions depend on physician preference, patient response, payer policy, and disease severity.
Principal competitors
| Product |
Company |
Route |
Main relevant indications |
| Cutaquig |
Octapharma |
SCIG |
Primary immunodeficiency, adult CIDP |
| Hizentra |
CSL Behring |
SCIG |
Primary immunodeficiency, CIDP |
| Cuvitru |
Takeda |
SCIG |
Primary immunodeficiency |
| HyQvia |
Takeda |
Facilitated SCIG |
Primary immunodeficiency |
| Xembify |
Grifols |
SCIG |
Primary immunodeficiency |
| Gamunex-C |
Grifols |
IVIG and SCIG |
Multiple immunoglobulin indications |
| Privigen |
CSL Behring |
IVIG |
Multiple immunoglobulin indications |
| Gammagard Liquid |
Takeda |
IVIG and SCIG |
Multiple immunoglobulin indications |
Hizentra is the most direct commercial comparator because it has a major SCIG franchise and a CIDP indication. Cuvitru competes strongly in primary immunodeficiency, while HyQvia offers a differentiated option for patients who prefer less frequent administration but can tolerate recombinant hyaluronidase-assisted delivery.
What is driving Cutaquig’s market growth?
Cutaquig’s growth drivers are commercial rather than patent-driven.
Home infusion adoption
Home administration reduces dependence on hospitals and infusion centers. The shift gained momentum during and after the COVID-19 pandemic and remains relevant because patients with chronic immunodeficiency often prefer greater treatment control and fewer clinic visits.
CIDP expansion
The CIDP indication gives Octapharma access to a larger and more specialized neurology market. It also increases physician exposure to Cutaquig among neurologists who may not prescribe the product for primary immunodeficiency.
The opportunity is constrained by established alternatives. Hizentra has a strong position in SCIG for CIDP, and IVIG remains entrenched for induction and maintenance therapy. Cutaquig must demonstrate reliable supply, tolerability, payer coverage, and patient persistence to gain share.
Plasma supply and manufacturing scale
Immunoglobulin manufacturers depend on plasma collection, fractionation capacity, quality control, and cold-chain distribution. Plasma supply has historically been a major constraint. Companies with diversified collection networks and integrated manufacturing have an advantage when demand exceeds available product.
Octapharma operates plasma collection and fractionation infrastructure across several regions. That vertical capability supports supply security, although it does not eliminate exposure to donor volume, regulatory controls, manufacturing interruptions, or demand spikes.
Product concentration
Cutaquig’s 16.5% concentration provides a differentiated product profile within the SCIG category. Lower administration volume can improve convenience for some patients. The commercial impact is limited where patients prioritize established devices, fewer infusion sessions, or reimbursement continuity over concentration.
What is Cutaquig’s financial trajectory?
Octapharma does not report Cutaquig revenue, gross margin, patient numbers, or prescription volume as separate financial line items. The product is part of a broader private-company portfolio that includes immunoglobulins, albumin, coagulation products, and hematology therapies.
Octapharma reported group sales of approximately €3 billion in recent annual reporting periods, with immunoglobulin products representing a major business area. Product-level Cutaquig performance is therefore not independently verifiable from public financial statements.[2]
Financial trajectory assessment
| Period |
Commercial interpretation |
| 2018-2020 |
Launch phase focused on primary immunodeficiency, physician education, and payer access |
| 2021-2022 |
Expansion of the commercial opportunity through CIDP approval and broader specialty-pharmacy access |
| 2023 onward |
Maturation phase characterized by competition with Hizentra, Cuvitru, Xembify, and IVIG products |
| Long term |
Growth depends on SCIG conversion, retention, international penetration, and reliable plasma supply |
The likely financial profile is a growth product within a larger immunoglobulin franchise rather than a standalone blockbuster with publicly visible revenue. Cutaquig can contribute attractive recurring revenue because patients often require long-term or lifelong replacement therapy. The product’s economics are moderated by plasma costs, manufacturing investment, specialty distribution, nursing services, payer rebates, and competition among immunoglobulin suppliers.
Revenue exposure
Cutaquig-specific revenue exposure cannot be calculated from Octapharma’s public reporting. A practical assessment uses four indicators:
- Growth in Octapharma’s immunoglobulin business.
- Expansion of Cutaquig’s approved indications.
- Growth in SCIG utilization relative to IVIG.
- Increases in Octapharma’s manufacturing and commercial infrastructure.
The product has recurring-demand characteristics, but its financial contribution is likely diluted within Octapharma’s broader product portfolio.
When does Cutaquig lose regulatory exclusivity?
Cutaquig is a biologic, not a conventional small-molecule drug. The U.S. exclusivity framework is therefore governed by the Biologics Price Competition and Innovation Act rather than the Hatch-Waxman generic framework.
The BLA reference-product exclusivity period is generally 12 years from first licensure. Based on the December 2018 U.S. approval, the principal U.S. reference-product exclusivity period would extend approximately through December 2030, subject to the legal treatment of the specific licensed application and any pediatric extension.[3]
A biosimilar sponsor could have filed a BLA after the applicable four-year statutory period, but commercial launch would remain constrained by reference-product exclusivity and patent rights. The end of regulatory exclusivity does not guarantee immediate competition. Biosimilar development requires analytical comparability, clinical or pharmacologic evidence where required, manufacturing validation, and commercial-scale plasma supply.
Biosimilar risk
The biosimilar threat to Cutaquig is different from generic risk:
- There is no automatic generic substitution.
- FDA approval requires a separate biologics license.
- Interchangeability is a separate regulatory designation.
- Manufacturing complexity and plasma supply reduce the number of potential entrants.
- Payers may encourage substitution without requiring pharmacy-level automatic substitution.
Biosimilar competition is likely to emerge first in large IVIG and SCIG categories with high demand and established payer contracts. Cutaquig’s 16.5% formulation, device configuration, and manufacturing process may create switching friction, but they do not provide permanent protection against biosimilar competition.
What patents and manufacturing rights protect Cutaquig?
Publicly available information does not provide a single, reliable product-specific patent list equivalent to the Orange Book entries used for small-molecule drugs. Biologic protection typically combines:
- BLA regulatory exclusivity.
- Composition and formulation patents.
- Manufacturing-process patents.
- Fill-finish and container-closure rights.
- Device or administration-system rights.
- Trade secrets covering plasma fractionation and purification.
- Contracting and supply-chain advantages.
Cutaquig is not expected to have an Orange Book listing in the same manner as an approved small-molecule tablet or capsule. Biologic patent disclosures and litigation procedures operate under the BPCIA framework and may involve the Purple Book, patent exchanges, and federal court litigation.
The strongest practical barriers are likely to be manufacturing know-how, plasma collection, quality systems, and regulatory compliance. Formulation patents may protect specific concentrations, stabilizers, purity characteristics, or manufacturing steps, but their commercial value depends on claim scope and remaining patent term. No material public Paragraph IV challenge or major Cutaquig patent litigation is established in the available record.
Which companies are challenging Cutaquig commercially?
The primary competitive pressure comes from established immunoglobulin manufacturers rather than a known Cutaquig-specific litigation campaign.
CSL Behring
CSL competes through Hizentra and a broad IVIG portfolio. Its scale, physician relationships, specialty pharmacy infrastructure, and CIDP experience make it the most direct competitive threat in SCIG.
Takeda
Takeda competes with Cuvitru, HyQvia, and Gammagard Liquid. HyQvia differentiates through less frequent facilitated subcutaneous administration, while Cuvitru competes directly in conventional SCIG.
Grifols
Grifols has a broad immunoglobulin franchise and plasma-collection infrastructure. Xembify adds direct SCIG competition, while Gamunex-C covers both IVIG and SCIG use cases.
New biosimilar manufacturers
Potential future entrants include companies with experience in plasma-derived products, recombinant delivery technologies, or biosimilar manufacturing. Entry is more likely to target the largest and most standardized immunoglobulin segments before specialized product configurations.
What generic launch scenarios exist for Cutaquig?
A conventional generic launch is not the relevant scenario. The principal scenarios are:
| Scenario |
Timing |
Commercial effect |
| No near-term biosimilar |
Before 2030 |
Cutaquig retains regulatory protection and competes mainly on access and product performance |
| Early biosimilar development |
Before 2030 |
Limited immediate price impact, but payer and investor expectations change |
| First biosimilar launch after exclusivity |
Around or after 2030 |
Discounts may pressure net pricing, especially in payer-controlled channels |
| Multiple biosimilar entrants |
After initial launch |
Greater price erosion and stronger switching incentives |
| Limited biosimilar entry |
After 2030 |
Plasma supply and manufacturing complexity preserve relatively high prices |
A biosimilar would not necessarily eliminate Cutaquig revenue. Patients may remain on the originator because of tolerability, infusion-site experience, physician preference, device familiarity, or stable reimbursement.
How strong is the Cutaquig competitive position?
Cutaquig has a credible but not dominant position in a growing SCIG segment.
Strengths
- 16.5% concentration supports lower administration volume for some patients.
- FDA-approved use in primary immunodeficiency and adult CIDP.
- Backing from a vertically integrated plasma-derived biologics manufacturer.
- Recurring demand from chronic therapy.
- Home-infusion alignment.
- Potential for international expansion.
Weaknesses
- Strong competition from Hizentra and Cuvitru.
- No publicly disclosed product-level revenue or market share.
- Dependence on plasma availability.
- Limited public visibility into patent duration and claim scope.
- Payer pressure in a high-cost specialty category.
- CIDP treatment decisions remain heavily influenced by IVIG familiarity.
Cutaquig’s patent strength is difficult to rank publicly because its commercial protection is likely distributed across regulatory exclusivity, manufacturing rights, and process know-how rather than a single high-value composition patent. Its business strength is more closely tied to supply reliability, clinical adoption, and payer positioning.
What litigation and settlement risks affect Cutaquig?
No major publicly established Paragraph IV litigation or settlement agreement involving Cutaquig is identified in the available record. This does not remove future risk. Potential disputes could arise over:
- Biosimilar patent claims.
- Manufacturing-process patents.
- Formulation or concentration claims.
- Device and administration rights.
- Patent-term calculations.
- Interchangeability or substitution practices.
- Contracting and reimbursement arrangements.
The absence of known litigation supports a relatively stable near-term commercial outlook, but it does not establish that all relevant patents are unchallenged or enforceable.
How does Cutaquig compare with Hizentra, Cuvitru, and HyQvia?
| Attribute |
Cutaquig |
Hizentra |
Cuvitru |
HyQvia |
| Manufacturer |
Octapharma |
CSL Behring |
Takeda |
Takeda |
| Route |
SCIG |
SCIG |
SCIG |
Facilitated SCIG |
| Concentration |
16.5% |
20% |
20% |
Immunoglobulin with hyaluronidase |
| CIDP positioning |
Approved maintenance use |
Strong direct competitor |
Primarily immunodeficiency |
Primarily immunodeficiency |
| Key differentiator |
High-concentration Octapharma platform |
Scale and established CIDP franchise |
High-concentration, larger-volume flexibility |
Less frequent administration |
| Main risk |
Competitive share capture |
Payer and biosimilar pressure |
Payer and portfolio competition |
Cost and administration complexity |
Cutaquig is best positioned against products that compete on conventional home SCIG. It is less directly comparable with HyQvia, which uses a different delivery approach and targets patients who value reduced administration frequency.
Key Takeaways
- Cutaquig is a 16.5% SCIG product from Octapharma for primary immunodeficiency and adult CIDP.
- Its market is supported by increased home infusion, chronic treatment demand, and SCIG conversion from IVIG.
- The strongest direct competitor is Hizentra, followed by Cuvitru and Xembify.
- Octapharma does not disclose Cutaquig-specific revenue, so product-level financial performance cannot be quantified from public filings.
- U.S. biologic reference-product exclusivity is expected to run approximately through December 2030 based on the December 2018 approval.
- Biosimilar entry, rather than conventional generic substitution, is the principal long-term erosion risk.
- Plasma supply, fractionation capacity, manufacturing know-how, and payer contracts are major commercial barriers.
- No major public Cutaquig Paragraph IV litigation or settlement is established in the available record.
- The product’s long-term value depends on CIDP uptake, SCIG market growth, retention, international expansion, and Octapharma’s supply reliability.
FAQs About Cutaquig Market and Financial Outlook
Is Cutaquig a blockbuster drug?
Cutaquig-specific revenue is not publicly reported, so its blockbuster status cannot be confirmed. Octapharma reports company-level results rather than product-level sales.
Is Cutaquig interchangeable with Hizentra?
Cutaquig and Hizentra are both SCIG products, but they are not automatically interchangeable. Switching depends on physician judgment, patient response, dosing, administration requirements, payer policy, and FDA interchangeability status.
Does Cutaquig have a biosimilar?
No established FDA-approved Cutaquig biosimilar is identified in the available public record. Future competition would require a biosimilar BLA and would likely face manufacturing and plasma-supply barriers.
Is Cutaquig covered by Medicare?
Coverage depends on the indication, route of administration, supplier, and Medicare benefit category. Patients may receive coverage through Part B, Part D, or other payer arrangements depending on clinical and delivery circumstances.
What is the biggest commercial risk for Cutaquig?
The largest commercial risk is loss of share to established SCIG products, particularly Hizentra and Cuvitru, rather than immediate patent-driven generic substitution. Long-term risk increases if biosimilar manufacturers achieve approval after the reference-product exclusivity period.
References
- U.S. Food and Drug Administration. (2018). Cutaquig prescribing information. FDA.
- Octapharma AG. (2023). Annual report 2023. Octapharma.
- U.S. Food and Drug Administration. (2023). Reference product exclusivity and biosimilar biological products. FDA.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- U.S. Food and Drug Administration. (2021). Cutaquig prescribing information: Chronic inflammatory demyelinating polyneuropathy indication. FDA.
